Baxter reports financial results

07/22/2010 | Wall Street Journal, The

Baxter International reported a decrease in earnings for the second quarter, owing to economic and product issues. The company expects sales of its plasma protein and antibody therapy products to decline for the rest of the year because of continued market issues. It also said it has stepped up its strategies to strengthen sales of Gammagard, a plasma-based drug.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC